logo

IMNN

Imunon·NASDAQ
--
--(--)
--
--(--)

IMNN fundamentals

Imunon (IMNN) released its earnings on Nov 13, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -1.16 (YoY -241.18%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-1.16
-241.18%
Report date
Nov 13, 2025
IMNN Earnings Call Summary for Q3,2025
  • OVATION 3 Enrollment Surging: 9 patients randomized by October 2025, exceeding internal targets.
  • Cost Efficiency: 31% YoY drop in operating expenses, $1.25M monthly cash burn.
  • Adaptive Trial Design: 95% statistical power with interim stopping rules for accelerated approval.
  • Regulatory Momentum: FDA-endorsed overall survival endpoint, European alignment in sight.
  • Partnership Progress: Active discussions with pharma companies for non-dilutive funding.
EPS
Revenue

Revenue & Expenses

Key Indicators

Imunon (IMNN) key financial stats and ratios, covering profitability, financial health, and leverage.
Imunon (IMNN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Imunon (IMNN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Imunon (IMNN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Imunon (IMNN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Imunon (IMNN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield